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ABSTrACT                        Ubiquitylation is an intracellular chemical reaction in which the small polypeptide, 
ubiquitin, is covalently attached to proteins to serve as a versatile signal with proteolytic and 
non-proteolytic functions. Although the importance of ubiquitylation was first recognized in 
the process of proteasome-mediated protein degradation, its regulatory potential has since 
been extended considerably. It is now known that through an elaborate and diverse set of 
ubiquitylating and deubiquitylating enzymes, the ubiquitin-proteasome system affects practically 
all intracellular processes. Not surprisingly, alterations in the ubiquitylating system have been 
linked to the development of various human diseases, including neurodegenerative disorders 
and cancer. Here, we highlight the most important components and processes of the UPS, and 
then demonstrate in a few examples connections between aberrations in ubiquitylation and 
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introduction
Proteins are basic constituents that ensure normal structure 
and operation of cells. First, back at the beginning of the 20st 
century, it was thought that proteins were quite stable, but 
by the early years of 1940s, Rudolph Schoenheimer showed 
that proteins maintain a steady state level in the cells through 
continuous synthesis and degradation (Schoenheimer 1942). 
Beside the synthesis of proteins, their degradation is also 
very important, since proteolysis determines their life-span, 
removes damaged or denatured proteins and replenish the 
amino acid pool of the cells. Therefore, effective protein 
degradation is essential for all organisms and indeed, most 
eukaryotic cells have such mechanisms. One of them is a 
vacuolar structure called the lysosome which was discovered 
in the 1950s by Christian de Duve (1953). The lysosomes 
are membrane-enclosed intracellular organelles that contain 
about 50 hydrolytic enzymes capable of breaking down just 
about everything at acidic pH. Another very effective prote-
olytic mechanism with an intricate specificity assurance is 
the ubiquitin-proteasome system (UPS). Unlike lysosomes, 
the UPS is not surrounded by membranes, instead a post-
translational modification, the ubiquitylation, serves as a 
chemical selectivity filter to prevent unwanted destruction 
(Ciechanover and Iwai 2004). In this pathway, a target 
protein is first tagged by multimers of a polypeptide called 
ubiquitin, and then it is selectively recognized and degraded 
in the “chamber of doom” of the cell, known as the protea-
some (Goldberg et al. 2001). The ubiquitylation process was 
discovered by the groundbreaking studies of Avram Hershko, 
Aaron Ciechanover and Irwin Rose, starting from the 1970s. 
We now know that the ubiquitylation is selective that can be 
modulated or even reversed by a process known as deubiq-
uitylation, and the outcome greatly affects the fate of target 
proteins. The degradation step in the UPS is confined only to 
the proteolytic central chamber of the proteasome. It became 
generally recognized that ubiquitylation-deubiquitylation 
and the subsequent degradation of nuclear and cytoplasmic 
proteins are essential in the regulation of many cellular pro-
cesses, such as intracellular quality control, cell proliferation, 
apoptosis or gene expression. Since many substrate proteins 
and many processes are involved in ubiquitylation, it is not 
surprising that malfunctions of the ubiquitin-proteasome 
system have been implicated – directly or indirectly – in the 
etiology of many inherited and acquired human diseases. In 
this review, we highlight the most important components and 
processes of the UPS, and then demonstrate in a few examples 
connections between aberrations in ubiquitylation and the 
pathogenesis of certain diseases. 
Serving as a label for the proteasomal degradation of 
proteins is, however, clearly not the only role through which 
ubiquitin and related proteins contribute to regulation of 
various cellular mechanisms. Following the overview of the 
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UPS system we will discuss briefly other ubiquitin-mediated 
processes and cover the roles of ubiquitin related proteins 
(URLs). Due to space limitation we restrict the discussion to 
general considerations on the versatility of posttranslational 
modifications by polypeptides and use histone modifications 
to serve as examples. 
Ubiquitin
The central component of the UPS is a highly conserved 
essential polypeptide of 76 amino acids, the ubiquitin. Only 
three of its amino acids differ from yeast to humans, and 
ubiquitin is present in all tissues of eukaryotes. Ubiquitin is 
encoded by a multigene family of five genes, three of them 
coding for tandem polyubiquitin precursors and two of them 
coding for ubiquitin - ribosomal protein fusion precursors 
(Nenoi et al. 2000). To generate active free monomers, 
post-translational cleavage of these precursors is required 
by deubiquitylating enzymes. When attached to a lysine 
side-chain of other proteins, ubiquitin serves as a signal that 
influences the fate, conformation, activity or the localiza-
tion of those proteins. Ubiquitin itself contains seven lysine 
residues (Fig. 1) all of which can serve as a site for ubiquitin 
linkage, the condition for the formation of polyubiquitin chain 
(Pickart 2001; Xu et al. 2009). Different cells have their own 
ubiquitin pool in which the ubiquitin exists either as free 
mono- and polyubiquitin or covalently conjugated mono- and 
polyubiquitin to other proteins (Kimura and Tanaka 2010). 
The total ubiquitin content of Human Embryonic Kidney 
293 (HEK 293) cells has been estimated as 8 x 107 copies 
per cell that corresponds to 0.42% (w/w) of total cellular 
proteins. It is estimated that about a quarter of the ubiquitin 
accounts for the free monoubiquitin pool. The majority of 
substrate-conjugated ubiquitin - 63% of the total ubiquitin 
pool - constitutes the monoubiquitylated forms and about half 
of these are present in a histone-enriched fraction. About 10% 
of ubiquitin is linked in polyubiquitin chains (Kaiser et al. 
2011; Heride et al. 2014). Considering everything, the level 
of free monoubiquitin in the cells is determined by ubiquitin 
synthesis, ubiquitylation and polyubiquitin chain formation, 
polyubiquitin chain disassembly and ubiquitin degradation.
The enzymatic cascade of ubiquitylation
Ubiquitylation is a process in which free ubiquitin is cova-
lently linked to target proteins through an isopeptide bond 
catalyzed by an enzyme cascade of at least three enzymes, 
termed ubiquitin-activating or E1, ubiquitin-conjugating or 
E2, and ubiquitin-ligating or E3 enzymes (Fig. 2) (Hershko 
and Ciechanover 1992; Varshavsky 1997). The isopeptide 
bond is formed between the carboxy-terminal glycine of 
ubiquitin and the ε-amino group of a lysine residue of the 
acceptor protein. The process starts with the activation of a 
free monoubiquitin (or more precisely, its carboxy-terminal 
glycine residue) that requires adenosine triphosphate (ATP) 
as an energy source and catalyzed by the E1 enzyme. This 
step results in the formation of a high energy thioester bond 
between the C-terminal carboxyl group of ubiquitin and the 
sulfhydryl group of the E1 active site cysteine. The activated 
ubiquitin is then transferred to the active site cysteine of an 
E2 enzyme via a trans-esterification reaction. In the final step 
of ubiquitylation an isopeptide bond is formed between a 
lysine of the target protein and the carboxy-terminal glycine 
of ubiquitin. In some cases, ubiquitin is transferred directly to 
target proteins by an E2, but in general, this reaction requires 
the participation of an E3 ubiquitin ligase, since generally 
the E3 enzymes interact with substrate proteins, that is, they 
determine the specificity of ubiquitylation. E3 enzymes have 
two subtypes: The HECT (Homologous to the E6-associated 
Figure 1. Diagram of ubiquitin. Lysine sidechains are shown in or-
ange. 
Figure 2. The ubiquitylation – deubiquitylation cycle. Ubiquitin is co-
valently attached to target proteins through ubiquitylation, which is a 
three-step process involving the E1, E2, E3 enzymes. Deubiquitinating 
enzymes (DUBs) reverse the ubiquitylation process (middle), process 




protein Carboxyl Terminus) domain containing E3s form a 
covalent E3-ubiquitin intermediate before transferring the 
ubiquitin to its substrate protein (Pickart 2001). The RING 
(Really Interesting New Gene) domain E3 ligases function as 
docking stations with both substrate and E2 binding modules 
in such a conformation that the E3 can catalyze the transfer 
of ubiquitin from the E2 to the substrate protein (Nagy et al. 
2012). Following the initial linkage of the first ubiquitin, a 
polyubiquitin chain can be formed by sequential binding of 
additional ubiquitins to each other through an internal lysine 
residue of the previously attached ubiquitin. In some cases, 
an additional elongation factor, named E4, appeared to be 
required for efficient polyubiquitylation and proteasomal 
targeting of a model substrate (Hoppe 2005). The enzymatic 
cascade of ubiquitylation in mammalian cells includes two 
E1 enzymes (UBA1 and UBA6), 40 E2s, and more than 600 
E3s belonging to one of the above mentioned two families 
(HECT, RING). A few RING proteins combine with any of 
seven cullin family members and a variety of adaptor proteins 
to create a diverse family of cullin-E3 ligases (see in Pickart 
and Eddins 2004 and references therein).
The fate of ubiquitylated target proteins depends in part on 
the length of the conjugated ubiquitin chain and on the topol-
ogy of ubiquitin–ubiquitin linkages within the ubiquitin chain. 
It is not yet clear how the length of the polyubiquitin chain is 
regulated, though it must be the result of the balanced action 
of ubiquitylating and deubiquitylating enzymes. However, 
it is known, that the lysine (Lys) residue of the ubiquitin on 
which polyubiquitylation takes place is important in terms of 
the fate of target proteins. While polyubiquitin chains (with 
at least four ubiquitin moieties) linked via Lys-11, Lys-29 
and Lys-48 will target proteins for proteasomal degradation, 
linkages via Lys-63 serve as signals for deoxyribonucleic acid 
(DNA) repair or intracellular signaling (Pickart and Fushman 
2004; Welchman et al. 2005; Jin et al. 2008). The functions of 
other chain topologies are much less known. Monoubiquityla-
tion can also have a variety of effects on protein function that 
do not include proteasomal degradation.
deubiquitylation
Similarly to other post-translational modifications of proteins, 
ubiquitylation is a reversible process. Ubiquitin is removed 
from proteins and polyubiquitin chains are processed by 
deubiquitylating enzymes called DUBs (Fig. 2) (Wing 2003). 
Since these enzymes attack the isopeptide bond between 
the ubiquitin and the target protein or another ubiquitin, the 
DUBs are members of the isopeptidase family of proteases 
and can be divided into two subfamilies based upon their 
mechanism of catalysis: cysteine- and metallo-proteases. 
Cysteine-protease DUBs contain a catalytic amino acid triad 
of cysteine-histidine-aspartate residues, while the metallo-
protease DUBs have a triad of two histidines and an aspartate 
residue and use a zinc atom for their activity (Ambroggio et 
al. 2004; Nijman et al. 2005). The cysteine-protease DUBs 
can be further subdivided into four classes based on their 
ubiquitin-protease domains: ubiquitin-specific proteases or 
USPs, ubiquitin C-terminal hydrolases or UCHs, Otubain 
proteases or OTUs and Machado-Joseph disease proteases 
or MJDs. All metallo-protease DUBs possess an ubiquitin-
protease domain called JAMM. In addition to their catalytic 
domains, DUBs also contain ubiquitin binding and various 
protein-protein interaction domains (Ventii and Wilkinson 
2008) that have roles in recognition and binding different 
ubiquitin-ubiquitin linkages and assembly of multiprotein 
complexes that localize DUBs.
The biological significance of DUBs is manifold. As 
mentioned above, by removing mono- and polyubiquitin 
chains from proteins they are able to reverse the effect of 
ubiquitylation signal. In a coordinated action with the ubiq-
uitylation enzyme cascade, they can edit or modulate the 
ubiquitylation signal. In addition to this, DUBs are involved 
in the processing of ubiquitin precursors that are the ubiquitin-
ubiquitin and ubiquitin-ribosomal protein fusion products of 
the ubiquitin genes (Fig. 2). Finally, an equally important 
function of DUBs is the recycling of free monoubiquitins by 
disassembling unconjugated polyubiquitin chains (Kovács 
et al. 2015). Ultimately, all DUBs are involved in ubiquitin 
recycling, but their relative roles are unclear. It is interesting 
that in addition to isopeptidase activity, many DUBs have es-
terase and amidase activities in vitro (Pickart and Rose 1985; 
Wilkinson et al. 1986). These activities could be important in 
vivo, since all cells contain high levels of nucleophile small 
molecules, like glutathione and polyamines, that can attack 
the reactive thioester bonds of ubiquitin-E1s and –E2s, and 
form ester and amid bonds with ubiquitins. Without esterase 
and amidase activities, the free ubiquitin content of the cells 
could be sequestered to these small molecules (Pickart and 
Rose 1985).
In the baker’s yeast, Drosophila and human genomes, 
there appear to be at least 21, 45 and 95 genes coding for 
DUBs, respectively. Their large number and their presence in 
multiprotein complexes suggest that they have specific effects 
and may have specific regulatory roles similarly to the ubiqui-
tylating enzymes. Generally, the DUB enzymes are much less 
characterized than their ubiquitylating counterparts.
The structure and function of the 
proteasome
Proteins modified by polyubiquitin chains are recognized 
and degraded by the proteasome. The proteasome is present 
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in both the cytoplasm and the nucleus of all eukaryotic cells 
(Adams 2003). The most prevalent form of the 26S protea-
some is a huge multiprotein protease complex consisting of 
a 20S core particle (CP) that is associated with one or two 
19S regulatory particles (RP) (Fig. 3). Each RPs contain 18 
different subunits, half of them forming a base and the other 
half forming a lid subcomplex (Pickart and Cohen 2004). The 
base subcomplex consists of six ATPases and the polyubiq-
uitin binding Rpn10 subunit, while the proteasome associated 
deubiquitylases reside in the lid. RPs are capable of binding 
polyubiquitin chains and removing them from the target 
protein. The substrate is then unfolded and translocated into 
the proteolytic chamber of the core particle. The core particle 
is a cylinder composed of four heptameric rings stacked on 
each other. The two outer or α-rings interact with the 19S 
regulatory particles, and form a narrow pore through which 
only denatured proteins can pass. The catalytic chamber is 
formed by the two inner β-rings, each of which contains three 
active sites. These sites differ in their substrate specificity and 
activity and have been named after enzymes that show similar 
proteolytic activity or specificity. These active sites are thus 
termed chymotrypsin-like, trypsin-like, and caspase-like. 
Proteins are degraded by the core particle in a progressive 
manner, generating peptides of 3-25 amino acids in length that 
can diffuse out through the other opening of the chamber.
The role of ubiquitin-mediated protein 
degradation in cell cycle regulation
The physiological functions of the UPS are being discovered 
at an accelerating pace. One of the best known and most 
important intracellular processes regulated by the UPS is the 
cell cycle. The cell cycle is an ordered series of unidirectional 
events by which cells duplicate their content, including their 
genomic DNA and segregate it into two daughter cells. The 
cell cycle is regulated primarily by oscillating activities of 
cyclin-dependent kinases or CDKs. The CDKs, in turn, are 
regulated by a superimposed complex network of proteins 
that constitute the cell cycle checkpoints and the UPS. The 
irreversible nature and precise timing of ubiquitin-mediated 
degradation of regulatory proteins are the factors that enable 
key transitions in the cell cycle, and ensure its unidirection-
ality. 
Although several hundred E3 ubiquitin ligases exist in 
eukaryotic cells, two of them have significant impact in cell 
cycle regulation: the anaphase promoting complex/cyclosome 
or APC/C and the Skp1-Cul1-F-box or SCF complex. Both 
of them are multisubunit enzymes, with similar scaffolding 
and catalytic modules but different substrate recognition and 
binding modules (Zachariae and Nasmyth 1999; Deák et al. 
2003; Nakayama and Nakayama 2005; Pál et al. 2007). An in-
triguing feature of the APC/C, that despite having an intricate 
structure of 13-15 subunits, the complex interacts with two 
activators, Cdc20 and Cdh1, which interact with the APC/C 
and contribute to its substrate binding in a cell cycle stage-
specific manner. The APC/C is active from prometaphase of 
mitosis till the end of G1, in which APC/CCdc20 triggers the 
metaphase-anaphase transition and sets up mitotic exit, APC/
CCdh1 regulates mitotic exit and helps to maintain G1 (Voder-
maier 2001). The SCF complex stays active throughout the 
cell cycle (Skaar and Pagano 2009).
Following the start of a new cell cycle, the activity of 
APC/CCdh1 maintains a stable G1, by ubiquitylating proteins 
involved in DNA replication, as well as S-phase and mitotic 
entry. This way proteins like Cdc6, Cdc25A, mitotic Cyclins 
A and B likewise mitotic kinases kept at low level through-
out G1 (Li and Zhang 2009). Any remaining Cyclin-CDK 
complexes are kept inactive by CDK inhibitors, or CKIs. 
Toward the end of G1, several mechanisms ensure the gradual 
inactivation of APC/CCdh1, which is mediated by the ubiqui-
tylation of the APC/C interacting E2 enzyme, UbcH10, and 
the phosphorylation and SCF-mediated degradation of Cdh1 
(Rape and Kirschner 2004; Skaar and Pagano 2009). Stable 
inactivation of the APC/CCdh1 occurs at the G1-S transition, 
when the production of the Emi1 inhibitor is induced by 
the E2F transcription factor, and that lasts till the end of G2 
(Hsu et al. 2002). In addition to the activation of the E2F-
type transcription factors, the G1-S transition is marked by 
rising G1/S- and S-specific CDK activities, and inactivation 
of the Retinoblastoma protein by phosphorylation. In this 
period, only the SCF complex is active and targets CKIs, 
such as p21, p27 and p57 for degradation, thus facilitating 
cell cycle progression through the S and G2 phases and up 
till the M phase (Tsvetkov et al. 1999; Kamura et al. 2003). 
Figure 3. Modular structure of the proteasome. The complex contains a 
20S core particle (CP) and one or two 19S regulatory particle (RP). The 
CP has a cylindrical shape and it is composed of four heptameric rings: 
two outer α-rings and two central β-rings. Three of the seven differ-
ent subunits of the β rings, β1, β2 and β5 show the distinct enzymatic 
activities of the proteasome. The RP is divided into two subcomplexes: 
the lid and the base.
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During S phase, the Cyclin E- and CyclinA-Cdk2 complexes 
are active and direct DNA replication and the duplication of 
centrosomes. After completion of DNA replication, Cyclin E 
becomes phosphorylated and tagged for degradation by the 
SCF complex (Koepp et al. 2001). During G2 progression, 
the cells get ready for one of the most fateful phase of the 
cell cycle, mitosis. 
The first part of mitosis is directed by the mitotic Cyclin 
B-Cdk1 complex. Although the Cyclin B-Cdk1 complex 
starts to accumulate in late G2, it is kept inactive by inhibi-
tory phosphorylation by Wee1-type kinases (Potapova et al. 
2011). At the G2-mitosis transition, the SCF complex facili-
tates mitotic entry by targeting Wee1 for ubiquitylation and 
fast proteasomal degradation. At the early phase of mitosis, 
the SCF complex also eliminates Emi1 and as a result, the 
APC/C becomes active (Margottin-Goguet et al. 2003), and 
from prometaphase, it becomes the key regulator of mitotic 
progression. First, the APC/CCdc20 triggers the metaphase-
anaphase transition by ubiquitylating the separase inhibitor, 
securin, and cyclin B1 for proteasomal degradation. In the 
absence of securin, the protease separase cleaves the cohesin 
complex and allows sister chromatid separation to occur (Zur 
and Brandeis 2001). Cyclin B1 degradation results in lower-
ing the activity of Cdk1, which further contributes to anaphase 
progression (Acquaviva and Pines 2006). Later in anaphase, 
Cdh1 binds to the APC/C, forming APC/CCdh1, and the two 
complexes together induce mitotic exit (Kramer et al. 2000) 
by completely inactivating Cdk1 through ubiquitin-mediated 
removal of Cyclin B. Following autoubiquitylation and APC/
CCdh1-mediated ubiquitylation of Cdc20, only the APC/CCdh1 
remains active in G1 (Reus et al. 2006; Foe et al. 2011).
Ubiquitin beyond proteasome-mediated 
protein degradation
Mono and polyubiquitylation, variations in 
ubiquitin chain structure and functions
In addition to protein degradation, ubiquitylation regulates 
protein function and localization and it is required for ba-
sic intracellular processes such as cell cycle control (as 
discussed above), transcription, DNA repair, apoptosis and 
several others. Ubiquitin modifications are critical for the 
formation of protein interaction networks and the activity of 
protein networks in space and time. Ubiquitin ligation can 
result in mono-, multi- or polyubiquitylated proteins (Fig. 
4). Multiubiquitylation could be the sum of monoubiquitin 
modifications of the same protein at multiple sites, while 
polyubiquitylation is the conjugation of one polyubiquitin 
chain to a single site. Internal lysine residues within the ubiq-
uitin polypeptide allow for chains of ubiquitin to be formed by 
progressive ubiquitylation events. Polyubiquitin chains may 
be constituted from a single or mixed linkage type and also 
from linkages that allow chain branching. Linear polyubiq-
uitin chains can also be formed by peptide-bond formation 
between the carboxyl group of the C-terminal glycine of one 
ubiquitin and the amino-terminal alpha–amino group of the 
methionine of another ubiquitin (Iwai et al. 2014).
The several types of ubiquitin chains represent a three-
dimensional code. Linkages through the different lysine resi-
dues diversify the position of neighboring ubiquitin molecules 
related to each other, thereby offering specific combinations 
of available surfaces and orientations. Consequently, linkage 
type and chain length are important parameters that can be 
interpreted by cellular machineries. Distinct chain types have 
been linked to specific steps of complex cellular processes; 
nonetheless the physiological roles of some types of ubiquitin 
chains are poorly understood. The most extensively studied 
function is targeting proteins for degradation through the 
recognition by the proteasome of Lys-48 linked polyubiq-
uitin chains. Although, it is believed, that all chain linkages 
with the probable exception of Lys63, may contribute to the 
proteasomal turnover of proteins, other linkage types are 
involved in other processes: specifically Lys-11 in cell-cycle 
regulation and Lys-63 in DNA repair and intracellular signal-
ing. Furthermore, for the efficient activation of retinoic acid 
inducible gene 1 three Lys-63-linked ubiquitins are required. 
According to a recent report, Lys-33 linked polyubiquityla-
tion promotes post-Golgi transport (Yuan et al. 2014). On the 
other hand Met1-linked linear ubiquitin chains are involved in 
nuclear factor–kappaB (NFκB) signaling and in the regulation 
of tumor necrosis factor (TNF)-mediated apoptosis (Iwai et 
al. 2014). For further details on atypical ubiquitylation see 
Kulathu and Komander 2012.
Figure 4. Ubiquitylation is variable in length and linkage type. Protein 
substrates can be monoubiquitylated with a single ubiquitin, multiu-
biquitylated with two or more monoubiquitins or polyubiquitylated. 
Polyubiquitins can be formed with different chain topologies – ex-
tended, closed or branched – depending on the lysine residues involved 
in the ubiquitin-ubiquitin linkages.
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The data above might well illustrate that ubiquitylation 
serves for a very complex signaling. A further increase in 
complexity can be achieved by the conversion of ubiquitin 
signals: a particular chain type can be removed partially 
and the remaining ubiquitin(s) targeted by another type of 
linkage(s). Indeed, ubiquitylation plays roles in most of 
the major cellular signaling pathways. One can view it as a 
specific code. It is also easily noticeable that this code has 
an integral quantitative feature as well: longer polyubiquitin 
chains can offer more binding sites thereby provide stronger 
signals as compared to shorter ones. The code is written by 
the ubiquitylating enzymes and erased or modified by the 
multitude of DUBs. Between these two classes of proteins 
act the readers of the code, those proteins which recognize 
the presence of mono and polyubiquitin signals via specific 
ubiquitin binding domains (UBDs). In the human genome 
there are at least 20 types of UBDs encoded within hundreds 
of proteins (Heride at al. 2014). The majority of UBDs rec-
ognize a hydrophobic patch in ubiquitin with Ile-44 in the 
middle. Since free ubiquitin is present in the cell in rather 
high concentration (10-20 μM range), the affinity of UBDs 
for monoubiquitin is necessarily low. The affinity for ubiq-
uitin chains is higher, due to the multiplicative effect of more 
than one binding sites. Indeed frequently ubiquitin binding 
proteins contain more than one UBD. Associations between 
UBD-containing proteins also provide more versatility. The 
combinatorial use of UBDs plays important role in determin-
ing ubiquitin chain specificity. Linkage specific avidity can 
arise from the detection of the distance between the individual 
molecules of a ubiquitin chain and the orientation of these 
molecules. The DNA repair protein, Rap80 for example has 
tandem ubiquitin binding domains separated by seven amino-
acid linker regions (Sims and Cohen 2009). This creates 
the ideal distance for association with ubiquitin molecules 
connected by a Lys-63 linkage. A shorter linker between the 
binding domains in ataxin-3 provides binding specificity for 
Lys-48 linkages. UBDs can be combined with various other 
domains and associated with multiprotein complexes thereby 
participating in versatile functions. With combination of 
DNA binding domains, UBD containing proteins and protein 
complexes can access chromatin to participate in specific 
functions as we will discuss in the next chapter. One role of 
the interaction of UBDs with ubiquitin chains might as well 
be to protect proteins from proteasomal degradation. 
Ubiquitylation and chromatin functions: the 
roles of H2A and H2B ubiquitylation
In eukaryotic cells octamers of four core histone proteins 
(H2A, H2B, H3 and H4) wrapped around twice by 146 bp 
of DNA form nucleosomes, the basic organization units of 
chromatin. From the arrays of nucleosomes highly ordered 
chromatin structures are formed through several levels of 
organization resulting in a high compaction of DNA in order 
to accommodate it in the restricted space of the nucleus. 
Interactions among chromatin constituents, however, restrict 
the accessibility of DNA to the cellular machinery, while 
on the other hand enable careful regulation of processes oc-
curring on the DNA template. The accessibility is regulated 
through various mechanisms, including the posttranslational 
modifications (PTMs) of histones. Most of the histone PTMs 
take place at the N-terminal tails of core histones, however, 
in smaller numbers, modifications can occure close to the 
C-terminal end. Among these are modifications of histone 
H2A and H2B at lysine 119 (K119) and lysine 120 (K120), 
respectively (the numbering of lysines refers to their positions 
in histones of higher eukaryotes). In fact histones are the 
most abundant ubiquitin conjugates in eukaryotes and histone 
H2A was the first protein identified to be monoubiquitylated 
(Goldknopf et al. 1975). In respect of histone modifications, 
ubiquitylation constitutes a major modification event as 
5-15% of H2A and 1-2% of H2B in mammalian cells is found 
in ubiquitylated form. (In yeast there is no detectable level of 
UbH2A.) The majority of UbH2A is in monoubiquitylated 
form, though polyubiquitylated H2A can also be detected. 
On H2B, only monoubiquitylation is detectable. Besides 
H2A and H2B histones H1, H2AZ, H3 and H4 have been 
also reported as substrates for ubiquitin modification but at 
lower levels than H2A and H2B (Jason et al. 2002; Zhang 
2003; Wang et al. 2006). 
Despite the fact that histone ubiquitylation was recognized 
a long time ago and that significant amounts of data have been 
collected indicating the role of these modifications in DNA 
repair and both up- and down-regulation of gene expression, 
a consensus on the role of the different histone ubiquityla-
tions is still missing. There are several possibilities how 
ubiquitylation might affect chromatin functions. Indirectly, 
ubiquitin can promote transcription or other chromatin medi-
ated processes by ensuring proteasome-mediated turnover of 
transcription factors or other regulators acting on DNA. More 
directly histone ubiquitylation may stabilize nucleosomes 
or affect higher-order chromatin structure, thereby affecting 
DNA accessibility. The ubiquitin is about half of the size of 
core histones, nonetheless nucleosomal particles with normal 
structure can be assembled when both H2A and H2B are 
replaced with their ubiquitylated counterparts (Davies and 
Lindsey 1994). K119 of H2A is in close proximity to the 
linker histone H1. It is therefore conceivable that ubiquityla-
tion affects chromatin folding at the chromatin fiber level. 
H2B ubiquitylation has been reported to increase nucleosomal 
stability in vivo. This is consistent with the finding that levels 
of UbH2B correlate with genome-wide nucleosome occu-
pancy. The enhancement of nucleosomal stability may restrict 
access of the transcriptional or replication machinery to the 
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DNA. Furthermore, histone H3 ubiquitylation at multiple sites 
has been demonstrated to play a role in nucleosome assembly 
(Han et al. 2013).
Ubiquitylated histones may also serve as signals for 
the recruitment of regulatory molecules that in turn affect 
transcription or repair. It was suggested that the dynamic 
ubiquitylation of H2B creates or destroys a binding site for 
a protein that acts as a reader of this particular modifica-
tion. The reader may serve to recruit other proteins. Among 
these could be other chromatin modifiers. Indeed, UbH2B 
facilitates H3K4 and H3K79 methylation by Dot1 and Set1 
methylases (Sun and Allis 2002). These marks are associ-
ated with active transcription. The role of UbH2B in tran-
scription, however, is more than facilitating other histone 
modifications. It seems that both the addition and removal 
of ubiquitin are critical for the transcription process. UbH2B 
deubiquitylation is performed by the USP22 protein that is 
present in the SAGA complex (Zhang et al. 2008). Inhibi-
tion of transcription elongation reduces the global level of 
UbH2B. This suggests that active transcription is required 
for maintaining UbH2B. Based on the global distribution 
of UbH2B it was proposed that UbH2B would repress the 
assembly of the transcription machinery at gene promoters 
but favor transcription elongation by promoting nucleosome 
reassembly in the wake of PolII. This is in accord with an 
observation that UbH2B was found exclusively at active 
genes, at the highest level just downstream of the TSS and its 
level decreases towards the 3’ end (Bonnet et al. 2014). The 
question, however, whether UbH2B in transcribed regions has 
a direct function in transcription elongation or whether this 
mark is a byproduct reflecting recent transcription remains 
to be resolved. The observation that blocking transcriptional 
elongation results in the loss of UbH2B from active genes, 
suggests that transcription itself maintains the dynamic state 
of H2B ubiquitylation. Replication stress also results in the 
gradual loss of global UbH2B. It is thus possible that DNA 
replication also maintains dynamic UbH2B. Based on these 
notions it was suggested that dynamic ubiquitylation results 
in a fluctuating chromatin environment necessary for tran-
scription and replication. Accordingly, ubiquitylation of H2B 
may enable the recruitment or retention of the transcription or 
replication machinery at chromatin, while deubiquitylation is 
required to enable the machinery to detach and advance along 
the DNA template (Wright and Kao 2015).
On the contrary to the genome-wide distribution of 
UbH2B, suppression of H2B ubiquitylation appears to have 
a mild effect on gene expression. Nonetheless, histone H2B 
monoubiquitylation is an evolutionarily conserved marker of 
gene activation. This histone signal is found in association 
with the transcribed regions of all expressed genes. Several 
other functions for UbH2B have also been reported. These 
are related to mRNA processing and cell differentiation, but 
the data on the exact roles are controversial (Espinosa 2008). 
Deregulation of UbH2B seems to be involved in cancer de-
velopment. This is suggested partly by the observation that 
USP22 that catalyzes the removal of the H2B ubiquitin mark 
was identified among an eleven-gene signature associated 
with poor cancer prognosis (Glinsky et al. 2005). The cancer 
connection is also supported by the fact that RNF20, the E3 
enzyme involved in UbH2B formation acts as a tumor sup-
pressor gene. Among others it positively regulates p53 as well 
(Kim et al. 2005). In mammals the major H2B E2 enzyme 
is RAD6, and the RING finger containing proteins RNF20 
and RNF40 are the major H2B E3 enzymes. Other factors, 
however, also have roles in UbH2B formation. 
H2A K119Ub has also been shown to play important 
roles in the regulation of essential genomic processes includ-
ing transcription, cell-cycle progression, and DNA damage 
response. Importantly H2A ubiquitylation marks silenced 
genes. The evolutionarily conserved polycomb repressive pro-
tein complexes (PRCs) ensure epigenetic repression of gene 
activity partly through H2A K119 monoubiquitylation. In 
addition to PRC-mediated homeotic gene repression, X chro-
mosome inactivation is also correlated with H2A K119Ub. 
The RING1B subunit that is the main E3 ligase responsible 
for H2A K119Ub formation is a PRC1 complex component 
(Wang et al. 2004; Scheuermann et al. 2012). 
Recently, novel sites, K13 and K15 on the histone H2A 
and its variant H2AX were shown to be the target of polyu-
biquitylation during DNA damage response (Mattiroli et 
al. 2012). Response to DNA double stranded breaks (DSB) 
activates a signaling cascade involving phosphorylation, 
ubiquitylation and SUMOylation events. The process is 
initiated by ATM-mediated phosphorylation of the histone 
variant H2AX and results in the recruitment of key repair 
factors to the breaks. At least six different ubiquitin ligases 
feature in this cascade. The modification events at the site 
of a DSB provide specificity to the localization of relevant 
repair factors and contribute to fine-tuning the amplitude 
of the response. There is a positive feedback built into the 
system which operates through the waves of ubiquitylation 
mediated by ubiquitin-binding E3 complexes. This results in 
an amplification of the signal. 
Ubiquitin-like proteins and their functions 
Ubiquitin is an evolutionary conserved prototype of a family 
of proteins that display remarkably similar structures, but 
variable sequences. As we mentioned above, the primary 
structure of ubiquitin differs only 3 of 76 positions between 
yeast and humans. Prokaryotes have no molecule that func-
tionally analogous to ubiquitin, but the ubiquitin fold is 
present in enzymes which participate in cofactor insertion 
into enzymes (ThiS and MoaD). In eukaryotes the ubiquitin 
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family encompasses nearly 20 proteins that are involved in 
the posttranslational modifications of various macromolecules 
(van der Veen and Ploegh 2012). The ubiquitin-like proteins 
(ULPs) that are part of this family adopt the β-grasp fold that 
is characteristic of ubiquitin. ULPs are very little related in 
sequence to ubiquitin but most importantly they display a 
highly similar three-dimensional structure. ULPs regulate a 
diverse set of cellular processes, including nuclear transport, 
proteolysis, translation, autophagy, antiviral pathways and 
many more. Most ULPs are conjugated to proteins via an 
enzymatic cascade that resembles ubiquitylation. The com-
mon biochemical mechanism of the ULP-mediated signaling 
is an isopeptide bond formation between the terminal glycine 
of the modifier and an amino group of the target protein. The 
general mechanism of action is thus the following: conjuga-
tion factors select the target, the modification then changes 
the properties of the substrate mostly by affecting protein-
protein interactions, finally downstream effectors recognize 
the modified substrate and transmit the signal of the modifica-
tion. Intriguingly, a certain type of ULP modification often 
affects enzymes participating in the formation of a different 
type of ULP modification.
The closest in sequence to ubiquitin is NEDD8, they 
share 58% identity. NEDD stands for neural precursor cell 
expressed, developmentally downregulated. The origin of 
the name stems from the observation that NEDD8 is one of 
ten, highly expressed proteins in embryonic mouse brain. 
NEDD8, similarly to the other extensively studied ULP, 
small-ubiquitin-related modifier (SUMO), is universally 
distributed in eukaryotes. In most eukaryotes neddylation 
is an essential protein modification pathway. Neddylation 
follows the routine of ubiquitylation: the NEDD8 activat-
ing enzyme is NAE, the E2 enzymes are Ubc12 and Ube2F, 
and there are several known NEDD8 E3 ligases (Rabut and 
Peter 2008). Despite the homology between NEDD8 and 
ubiquitin, NAE and Ubc12 are strictly specific. Under certain 
conditions, however, (NEDD8 overexpression, low ubiquitin 
level,) atypical neddylation can happen by ubiquitylating 
enzymes. Neddylation is mostly mononeddylation, although 
polyneddylation can also take place. The function of the lat-
ter is unknown. Removal of NEDD8, the deneddylation, is 
done by zinc-dependent metalloenzymes (van der Veen and 
Ploegh 2012).
The best studied targets of neddylation are the cullin fam-
ily proteins. These are scaffold proteins for the assembly of 
RING E3 ligase complexes (CRLs: cullin RING E3 ligases) 
that are involved in targeting substrates for proteasomal deg-
radation. Many CRL targets are cell cycle regulators. Mono-
neddylation stimulates the ubiquitylation activity of CRLs 
(Watson et al. 2011). The tumorsuppressor p53 can also be 
neddylated. Several pathogens interfere with the neddylation 
pathway (Chlamydia, Plasmodium, Escherichia coli) (van der 
Veen and Ploegh 2012). Since the targets of neddylation, the 
cullin proteins are important cell cycle regulators; neddylation 
can be a target for controlling cancer cell proliferation. A se-
lective inhibitor of NAE inhibits the growth of several tumors 
and, at present, it is in clinical trial (Soucy et al. 2009). 
The small-ubiquitin-related modifier (SUMO) shows 
less sequence similarity to ubiquitin than NEDD8: human 
SUMO1 is only 20% identical to human ubiquitin. Although 
SUMO is also an evolutionarily conserved protein as the hu-
man SUMO is 52% identical to the yeast SUMO. In vertebrate 
genomes, there are four SUMO genes. The products of these 
differ in their cellular localization. The paralogs are specific 
to a subset of targets. Hundreds of SUMO substrates have 
been identified. Many of these contain a consensus acceptor 
site (ψKχE, where ψ is large hydrophobic and χ any amino 
acid residue), and can form polymeric K11-linked chains 
(Sampson et al. 2001). SUMO chains are recognized by the 
SUMO-interaction motifs (SIMs). These form a beta-strand 
that can be inserted between the alfa-helix and beta-strand 
of SUMO. Many proteins contain SUMO binding sites that 
conform to this consensus motif. SIMs are also present in 
several SUMO substrates, such as, the transcription factors 
promyelocytic leukemia protein (PML) and death domain as-
sociated protein (Daxx), and the base excision repair enzyme 
thymine DNA glycosylase (TDG) (van der Veen and Ploegh 
2012). SIMs are also found in SUMO enzymes: SUMO E3 
ligases (PIAS, RanBP2) and the SUMO E2 enzyme Ubc9. 
Tandem SIMs are found in the ubiquitin E3 ligase RNF4. 
Interactions between the four SIMs of RNF4 and SUMO are 
essential for the ubiquitylation and degradation of SUMOy-
lated PML and poly(ADP-ribose) polymerase (PARP-1) 
(Tatham et al. 2008). The ubiquitin polymer can be linked 
directly to the substrate or to the poly SUMO chain. RNF4 
was the first recognized SUMO-targeted ubiquitin ligase. It 
can regulate intracellular localization of proteins, as it is in 
the case of HTLV transcriptional regulator Tax (Fryrear et 
al. 2012). SUMOylation also regulates nucleo-cytoplasmic 
transport and cell cycle progression by modulating the 
localization and activity of the substrates. Furthermore, 
SUMOylation regulates nuclear organization, transcription, 
chromatin remodeling, DNA repair and ribosomal biogenesis. 
SUMOylation of a protein can modify its DNA-binding prop-
erties. SUMO exerts mostly but not exclusively a repressive 
effect on gene activity. This can be achieved for example by 
recruiting co-repressors such as histone deacetylases. In the 
context of DNA repair, ubiquitin and SUMO interplay with 
each other in several pathways, such as in double-strand break 
repair by homologous recombination, non-homologous end 
joining, nucleotide and base excision repair and the bypass 
of replication fork-stalling lesions during DNA replication 
(Ulrich 2014). Oxidative and hypoxic stress also results in 
increased SUMO conjugation. Several pathogens interact 
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with the host SUMOylation pathway. In many cases, however 
we still do not know the functional consequences of substrate 
modification by SUMO. The proteases which remove SUMO 
moieties are the sentrin-specific proteases (SENPs). 
Interferon-stimulated gene 15 (ISG15) is one of the first 
ULPs identified. It is also called ubiquitin cross-reactive 
protein (UCRP). The linear diubiquitin analog ISG15 expres-
sion is induced by bacterial lipopolysaccharides (LPS), viral 
dsRNA and interferons alpha and beta (Jeon et al. 2010). 
ISGylation also involves an enzyme cascade resembling 
ubiquitylation. ISG15 is present in higher eukaryotes which 
produce interferons. ISG15 conjugation plays a role in nor-
mal development and interferon-mediated responses to viral 
infection. ISG targets are both cellular and viral proteins. ISG 
deficient mice are more susceptible to viral infection (van 
der Veen and Ploegh 2012). ISGylation also effects infection 
by influenza, HIV and ebola viruses. ISGylation of 10% of 
HPV capsid protein decreases the viral infectivity by 70%. 
ISGylation seems to be less target-specific than ubiquityla-
tion and it is supposed that it takes place co-translationally 
(Durfee et al. 2010). 
In addition to the ULPs discussed above, there are several 
less well characterized ULPs. Some of these are single do-
main proteins others are linear diubiquitin analogs like ISG15. 
Furthermore, new members of the ubiquitin family have just 
been discovered recently (Urm1 and Hub1) (van der Veen 
and Ploegh 2012). Some ULPs are found only in mammals 
and play roles in cytokine induced apoptosis. The function 
of others, however, remains unknown. It is interesting to note 
that the evolutionarily newer functions of some of these ULPs 
are in accord with their recent appearance in evolution.
Medical significance of ubiquitylation 
Ubiquitylation and ubiquitin mediated degradation of pro-
teins are involved in many essential intracellular processes. 
Therefore, it is not surprising that inherited or acquired 
disruptions of the ubiquitin-proteasome system and/or the 
ubiquitin related protein-mediated signaling systems have 
been linked to many inherited and acquired human diseases. 
Most of these abnormalities can be linked to loss of function 
mutations, however, gain of function mutations were also 
identified. Concerning tumor development, depending on 
the nature of the substrate a ubiquitin ligase can act both as 
an oncogene and as a tumor suppressor. Therefore ubiquitin 
ligases are attractive drug targets as they are the specificity-
conferring components in the ubiquitylation process. Increas-
ing evidences suggest that there is a crosstalk between the 
ubiquitin family members. Examples can be seen for this in 
that the conjugation of SUMO to certain substrates can defend 
them against modification by ubiquitin. Or that NEDD8, the 
closest relative of ubiquitin modifies cullin E3 ligases and 
thereby stimulates these enzymes to become more active in 
the conjugation of ubiquitin to cognate substrates. Malfunc-
tion of several components of the ubiquitylation pathway are 
directly linked to pathological states. Here two of the UPS 
related diseases, a neurodegenerative disorder and a malig-
nancy, are presented briefly.
Parkinson’s disease is a progressive neurodegenerative 
disorder. It is characterized by tremor, locomotory difficulties 
and stiffened posture. The main neuronal phenotype seen in 
patients with Parkinson’s disease is the loss of dopaminergic 
neurons in the substantia nigra. This results in a severe deple-
tion of dopamine, and the appearance of characteristic eosino-
phil inclusions known as Lewy bodies in the degenerating 
dopaminergic neurons (Forno 1996). Evidence implicating a 
direct role for the UPS in Parkinson’s disease came from the 
association of genetic mutations in the parkin gene with a spe-
cial form of familial Parkinson’s disease. Parkin is an E3 ubiq-
uitin ligase that, in normal cells, tags specific proteins with 
polyubiquitin, targeting them for degradation in the protea-
some. One of the proteins that Parkin normally ubiquitylates 
for destruction is α-synuclein, a neuronal protein with a not 
well understood function. Loss of function parkin mutations 
results in failure of proteasomal degradation of α-synuclein, 
and the subsequent increase in α-synuclein stability and 
concentration can promote aggregation of α-synuclein lead-
ing eventually to the death of dopaminergic neurons. A more 
complex involvement of the UPS in Parkinson’s disease was 
further highlighted in case studies that revealed mutations 
in other components, such as the UCH-L1 deubiquitylating 
enzyme as causative agents (Leroy et al. 1998).
Von Hippel-Lindau syndrome is an inherited disease 
characterized by the formation of hemangioblastomas and 
retinal angiomatosis which are tumors of the blood vessels 
that can form in many different parts of the body (Neumann 
et al. 1995). These tumors can be either cancerous or non-
cancerous, but even in noncancerous forms, they can cause 
serious, sometimes life-threatening complications. The gene 
disrupted in Von Hippel-Lindau syndrome is a tumor sup-
pressor gene that encodes a subunit of an E3 ubiquitin ligase 
termed the VHL-complex. The primary function of the VHL 
complex is to regulate the stability of the HIF (hypoxia induc-
ible factor) transcriptional complex by targeting HIF subunits 
for ubiquitylation and rapid proteasomal degradation under 
normal oxygen levels (Gossage et al. 2015). At low oxygen 
concentration that is in hypoxic conditions, the HIF tran-
scription factor is stabilized and upregulates the expression 
of several genes involved in cell proliferation, angiogenesis, 
and the production of red blood cells, such as vascular en-
dothelial growth factor (VEGF) and transforming growth 
factor alpha (TGF-α) (Wizigmann-Voos et al. 1995). When 
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VHL function is lost, the VHL-complex cannot target the HIF 
subunits for degradation, and as a result, HIF can accumulate 
in cells. Excess HIF brings about abnormal cell proliferation 
and undesired production of new blood vessels. Rapid and 
uncontrolled cell division, along with the abnormal formation 
of new blood vessels, can lead to the development of tumors 
in patients with von Hippel-Lindau syndrome.
In accord with key functions ubiquitin and related protein 
modifications fulfill, drugs interfering with them are studied 
extensively to modulate these functions. The proteasome in-
hibitor bortezomib has been used to treat tens of thousands of 
cancer patients. MLN-4924, an inhibitor that blocks an E1 for 
the ubiquitin-like molecule NEDD8, is also very promising 
in clinical trials. Thalidomide binds to celebron a component 
of a cullin E3 ligase complex. It is used to treat multiple 
myeloma (Heride et al. 2014).
Conclusions
Ubiquitin and ubiquitin-like modifiers are key components 
of very versatile mechanisms by which multitudes of protein 
functions, protein-protein interactions, intracellular protein 
localization, and protein turnover are regulated in eukaryotic 
cells. The basic features of the mechanism of protein modi-
fication by linkage to other protein(s) seem to be evolution-
arily conserved. The numbers of used polypeptide moieties, 
the variations of linkage types and resulting polymer chain 
structures are increasing with evolution and newer types of 
signals serve more recent functions. Polypeptide chains as 
posttranslational signals offer great variability and specificity 
for the signaling pathways that use them and include features 
permitting qualitative responses and signal amplification. 
The importance of the ubiquitin-proteasome system and the 
central role of ubiquitylation in several aspects of cell life 
are well documented. Concerning the role of other related 
modifiers our knowledge is more limited. To accumulate 
further information on them is highly warranted as both the 
proteasome-mediated protein degradation and the ubiquitin 
and related proteins mediated signaling pathways offer plenty 
of specific targets for inventions in pathological cases. 
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